Biosion

Biosion is a global clinical stage biotechnology company developing innovative biologics to address resistant, relapsed and residual disease for patients worldwide. Established in 2017, Biosion has assembled a world-class team with extensive global biologics development experience, and built an oncology and auto-immune focused pipeline of innovative biologics through its internally-derived proprietary technologies, including the H3 antibody discovery platform, SynAb™ synergistic antibody platform, SynTracer™ HT-endocytosis platform, and Flexibody™ bispecific platform and external source of innovation. The lead asset BSI-045B (anti-TSLP mAb) is currently in a global phase I clinical trial, with multiple assets expected to reach the clinic in 2022. Biosion has operations in the US, Australia and China. The mission of Biosion is to discover and develop innovative biologics through the synergy of great science, cutting-edge technologies and superior craftmanship for patients worldwide. Biosion has global collaborations with Celldex (NASDAQ:CLDX), Chiatai Tianqing (CTTQ, subsidiary of Sino Biopharm, HK:1177) and OBI Pharma (TWO:4174) and is actively seeking global partners who are interested in licensing, partnership or co-development opportunities.